Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.49 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.49 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.49 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.49 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.49 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4F8 | P98187 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020140 | 0.86 | ABL1 (0.59) | BRD4CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2098600 | 0.85 | ABL1 (0.63) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL3455245 | 0.82 | ABL1 (0.60) | BRD4CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL13211663 | 0.82 | ABL1 (0.60) | BRD4CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL964681 | 0.81 | RXRA (0.49) | CYP3A4ALDH1A1LMNANPC1TP53 | |
| SCHEMBL2034394 | 0.80 | MAOB (0.52) | BRD4CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL321834 | 0.79 | CASR (0.57) | BRD4CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL5849737 | 0.79 | CYP1A1 (0.65) | BRD4CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL22127110 | 0.79 | ENPP2 (0.53) | BRD4CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2355648 | 0.79 | ABL1 (0.60) | CLK4LMNAABL1ABCB1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-06 | — | — | US | claimed |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-01-13 | — | — | US | claimed |
| US-7759338-B2 | Soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | claimed |
| EP-2152080-A1 | NOVEL SOLUBLE 1,4 BENZODIAZEPINE COMPOUNDS AND STABLE SALTS THEREOF | The Regents of the University of Michigan (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008133635-A1 | NOVEL SOLUBLE 1,4 BENZODIAZEPINE COMPOUNDS AND STABLE SALTS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-11-06 | — | — | WO | claimed |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-13 | — | — | US | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-01-13 | — | — | US | disclosed |
| US-7759338-B2 | Soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| EP-2152080-A1 | NOVEL SOLUBLE 1,4 BENZODIAZEPINE COMPOUNDS AND STABLE SALTS THEREOF | The Regents of the University of Michigan (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-13 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245238-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | GABRA4, BAD, GABRA1 | BRD4 299/4885CYP1A1 1236/4885CYP1A2 1374/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | BRD4 1012/4885CYP1A1 1394/4885CYP1A2 659/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | BRD4 552/4885CYP1A1 1306/4885CYP1A2 420/4885 |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | GABRA4, BAD, GABRA1 | BRD4 299/4885CYP1A1 1236/4885CYP1A2 1374/4885 |
| US-20110009393-A1 | Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof | GABRA4, BAD, GABRA1 | BRD4 299/4885CYP1A1 1236/4885CYP1A2 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.